Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Tumori|October 10, 2014
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysisElena Collovà, Antonella Ferzi, Giuseppa Scandurra, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Tumori|July 14, 2015
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncologyGaetano Aurilio, Stefania Gori, Franco Nolè, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2020
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)Christoph Seidel, Gedske Daugaard, Tim Nestler, et al.
World Journal of Urology|March 8, 2021
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)Christoph Seidel, Gedske Daugaard, Tim Nestler, et al.
Therapeutic Advances in Medical Oncology|April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based studyKlaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Pageof 7